ClinicalTrials.gg
CompletedNCT03438929Updated May 22, 2018

Evaluation of Diolaze XL Blended Mode for Hair Removal

An interventional study of Diode laser in Hair Removal, sponsored by InMode MD Ltd.. Completed at 1 site in Israel. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-22.

Sponsored by InMode MD Ltd. (part of InMode Ltd.) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2017, registered Feb 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The objective of this clinical study is to evaluate safety and efficiency of Diolase XL blended modes for hair removal. The handpieces tested were a blend of 755nm/810nm and 810nm/1064nm. At least 30 female subjects seeking hair removal treatment will be enrolled. Treatment sites will be o groins and axillae. Study design included 3 treatment sessions 4 weeks apart and follow-up after 3 months.

02

Conditions studied

  • Hair Removal
03

In context

Lead sponsor

InMode MD Ltd. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult females between the ages of 18-65, seeking hair removal treatments.
  • Subjects skin type II-V.
  • Subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects, and sign the Form, (including the permission to use photography).
  • Subjects should be willing to comply with the study procedure and schedule, including the follow up visit, to refrain from using any other aesthetic treatment methods in the treatment areas such as other hair removal methods (wax, IPL, laser), Botox or other technologies for hyperhidrosis or rejuvenation for the last 6 months and during the entire study period and to remain unshaven for a minimum of 3 days before their visit.

Exclusion criteria

Exclusion Criteria:

  • Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles.
  • Pregnancy and nursing.
  • Impaired immune system due to diseases such as AIDS and , or use of immunosuppressive medications.
  • Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes, thyroid dysfunction, polycystic ovary and hormonal virilization.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
  • Severe concurrent conditions, such as cardiac disorders, sensory disturbances.
  • Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
  • Known skin photosensitivity or using drugs increasing skin photosensitivity.
  • Diseases that may be stimulated by light, such as epilepsy, lupus and urticaria.
  • Six months delay is recommended if other recent treatments like light, laser or RF were performed on the same area.
  • Treating over tattoo and permanent make-up.
  • Fresh tan from sun, sunbeds or chemicals or planned excessive sun exposure.
  • Vitiligo.
  • As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Interventions

  • DeviceDiode laser

    Diolaze XL blended modes diode laser

06

What researchers measure

Primary outcomes

  1. Hair reduction

    Hair reduction of at least 30% at follow-up visit comparing to baseline count.

    Time frame: 3 months follow-up

  2. Recording of frequency, severity and causality of adverse events (Safety)

    Observation, assessment and recording of reactions by the investigator.

    Time frame: 3 months follow-up

07

Study locations

1 site
  • InMode MD Ltd.
    Yokneam, 20692, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jan 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2018
First posted
Feb 20, 2018
StartActual
Aug 14, 2017
Primary completionActual
Jan 30, 2018
CompletionActual
Feb 10, 2018
Last update
May 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03438929
Lead sponsor
InMode MD Ltd.
Responsible party
Sponsor
First posted
Feb 20, 2018
Start date
Aug 14, 2017
Primary completion
Jan 30, 2018
Completion
Feb 10, 2018
Last update
May 22, 2018

Study contacts

Hela Goren, Ph.D.
study director · InMode MD Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion